GERRESHEIMER



Close-up Medical Plastic Systems

Gerresheimer Capital Markets Day

October 23+24, 2008

Dr. Axel Herberg, CEO



Disclaimer

- This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein.
- The Company does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does the Company accept any responsibility for the future accuracy of the opinions expressed in this Presentation or the actual occurrence of the forecast development.
- No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company or any of its parent or subsidiary undertakings or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

1

Gerresheimer at a glance 2007 Sales in EUR m













Tubular Glass (Injectable Glass and Systems)

Net sales: EUR 271m Adj. EBITDA margin: 24.6% Plastic Systems (Plastic Drug Delivery and Systems)


Net sales: EUR 300m Adj. EBITDA margin: 18.7% **Moulded Glass**

Net sales: EUR 319m Adj. EBITDA margin: 20.4% Life Science Research


> EUR 72m 10.7%

¹ Includes 11 months of sales generated by the Consumer Healthcare Business (EUR 22.4m); the business was disposed of effective June 1, 2008











Medical Plastic Systems is composed of two product areas Medical Plastic Systems Diagnostics **Pharma** Inhalation **Diabetes Care** Injection Laboratory & Molecular **Other Diagnostics** Pens



- Turbuhaler (AstraZeneca): Multidose-Dry-Powder-Inhaler -








- Novolizer (Almirall): Multidose-Dry-Powder-Inhaler -







- Respimat® Soft Inhaler (Boehringer Ingelheim): Active Dosing Aerosol without Propellant -







- HandiHaler® (Boehringer Ingelheim): Inhaler for the treatment of COPD (chronic-obstructive bronchitis) -







Gerresheimer Wilden Pharma: Injection

- Tamper Evident Seals for Syringe Systems -







Gerresheimer Wilden Pharma: Injection – Insulin pen (Novo Nordisk)





Gerresheimer Wilden Pharma: Diabetes Diagnostics

- ACCU-CHEK® Softclix (Roche Diagnostics): Lancing Device -







Gerresheimer Wilden Pharma: Diabetes Diagnostics

-ACCU-CHEK® Multiclix (Roche Diagnostics):
-Lancing Device with 6-lancet-drum -







Gerresheimer Wilden Pharma: Diabetes Diagnostics

- Lancets for Lancing Devices (Roche Diagnostics) -








Gerresheimer Wilden Pharma: Laboratory Diagnostics

- Cuvettes (Roche Diagnostics) -











Growth drivers Gerresheimer Wilden Medical Plastic Systems





Business model Medical Plastic Systems




Technical Competence Center (TCC) – Location Wackersdorf, Germany

- Concentration of technological expertise at one location
- Engineering of new products together with the customer
- Enforcement of worldwide uniform production standards
- Material and pharmaceutical laboratory, measuring room with product-specific testing equipment
- Permanent exchange program with research establishments and universities



Production facilities Medical Plastic Systems



Pfreimd, GERMANY

Kuessnacht, SWITZERLAND

Horšovský Týn, CZECH REPUBLIC







Dongguan City, close to Hongkong CHINA

Peachtree City, close to Atlanta USA






Location Pfreimd, Germany

■ Production area 10,200 m²

-of that, clean room area: 6,300 m² that, controlled area: 3,400 m²

- Key products: Inhalers, diagnostic devices
- Production strategy
 - Highly automated assembly process;
 high volume series
 - Start-up production facility for new products and processes
 - Competence in pharmaceutical services





Location Kuessnacht, Switzerland

■ Production area 3,500 m²

−of that, clean room area: 2,300 m²

-of that, controlled area: 800 m²

Key products: Cuvettes

- Production strategy
 - Highly automated processes in line with high output injection molding
 - Competence in reaction vessels and cuvettes





Location Horšovský Týn, Czech Republic

■ Production area 4,903 m²

−of that, clean room area: 1,596 m²

−of that, controlled area: 2,840 m²

Key products: Pens and Inhalers

Production strategy
 Manual, semi-automated and highly automated assembly process; injection molding low to high volume series



Location Peachtree City, USA

Production area

of that, clean room area: 800 m²

3,000 m²

-of that, controlled area: 800 m²

- Key product: Inhalers
- Production strategy
 - Highly automated assembly processes; medium to high volume series
 - Highly automated injection molding process
- Ramp-up of inhaler production





Location Dongguan City, China

■ Production area 1,710 m²

−of that, clean room area: 630 m²

-of that, controlled area: 900 m²

- Production strategy
 Mainly manual and semi-manual assembly processes
- Platform for future growth in China/Asia





Key criteria for successful manufacturing of drug delivery devices

- Track record of successful pharma production
- Regulatory experience
- Excellent knowledge in injection molding and assembly technology
- Constant process improvements
- Critical plant size necessary to allow for scale effects as well as high utilization and productivity



Only a few companies worldwide are able to truly fulfill pharmaceutical customer requirements



Medical Plastic Systems - A one-stop shop

